Talos Energyの空売り状況は、投資家がTalos Energyの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Talos Energy (NYSE:TALO) 株価情報, 空売り情報

Talos Energy

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？Bilibili Inc.は（NASDAQ：BILI）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、21ドルの株価予測を発表しました。

中国配信大手ビリビリ　株価が23%の高騰

Talos Energy Inc

Talon Energy Ltd

TALON INTERNATIONAL INC by Talon International, Inc.

Talon International Inc

Talon Metals Corp

<p>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Fluence Energy, revealing an average target of $21.0, a high estimate of $34.00, and a low estimate of $10.00. Highlighting a 19.48% decrease, the current average has fallen from the previous average price target of $26.08. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739307672_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Fluence Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ryan Levine</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Tom Curran</td>
<td>Seaport Global</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Shelby Tucker</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fluence Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fluence Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Fluence Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Fluence Energy's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FLNC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fluence Energy analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Fluence Energy</h2>
<p>Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.</p>
<h3>Financial Milestones: Fluence Energy's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Fluence Energy displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>82.49%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>3.9%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Fluence Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>10.71%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Fluence Energy's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.66%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.06</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

FLNC

A Glimpse Into The Expert Outlook On Fluence Energy Through 12 Analysts

<p>Throughout the last three months, 4 analysts have evaluated Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $139.0, a high estimate of $175.00, and a low estimate of $111.00. A decline of 0.71% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739307660_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Praxis Precision Medicine by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$111.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Praxis Precision Medicine. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Praxis Precision Medicine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Praxis Precision Medicine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Praxis Precision Medicine's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRAX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Praxis Precision Medicine analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Praxis Precision Medicine</h2>
<p>Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.</p>
<h3>Key Indicators: Praxis Precision Medicine's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Praxis Precision Medicine's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-35.47%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Praxis Precision Medicine's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-17188.74%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-12.95%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Praxis Precision Medicine's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-12.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PRAX

The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts

<p>Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $221.17, a high estimate of $244.00, and a low estimate of $183.00. This upward trend is apparent, with the current average reflecting a 5.48% increase from the previous average price target of $209.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739307648_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Allstate by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$187.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$243.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$183.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$244.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$209.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allstate. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allstate compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Allstate's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Allstate's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Allstate analyst ratings.</strong></a></p>
<h2>Delving into Allstate's Background</h2>
<p>Allstate is one of the largest us property-casualty insurers in the us. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.</p>
<h3>Allstate: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Allstate's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>14.69%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Allstate's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>6.98%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Allstate's ROE excels beyond industry benchmarks, reaching <strong>6.55%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Allstate's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.05%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Allstate's debt-to-equity ratio surpasses industry norms, standing at <strong>0.43</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Allstate's Future

<p>Analysts' ratings for ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.26, a high estimate of $12.00, and a low estimate of $8.50. Highlighting a 3.02% decrease, the current average has fallen from the previous average price target of $10.58. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739307638_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of ZoomInfo Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$9.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$10.30</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$8.50</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ZoomInfo Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ZoomInfo Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for ZoomInfo Technologies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ZoomInfo Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ZoomInfo Technologies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind ZoomInfo Technologies</h2>
<p>ZoomInfo Technologies Inc provides a go-to-market intelligence platform for sales and marketing teams. Its cloud-based go-to-market data and insights platform deliver comprehensive and high-quality intelligence and analytics to provide sales and marketing professionals with accurate information and insights on the organizations and professionals. Nearly all of its revenue is derived from the United States.</p>
<h3>ZoomInfo Technologies's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, ZoomInfo Technologies faced challenges, resulting in a decline of approximately <strong>-3.25%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> ZoomInfo Technologies's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.84%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ZoomInfo Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.35%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.36%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> ZoomInfo Technologies's debt-to-equity ratio surpasses industry norms, standing at <strong>0.82</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About ZoomInfo Technologies Stock

<p>Ukrainian President <strong>Volodymyr Zelenskyy</strong> is considering offering Russia a direct land exchange to end the nearly three-year war if President <a href="https://www.benzinga.com/topic/ukraine"><strong>Donald Trump</strong> brokers negotiations.</a></p>
<p>The unprecedented proposal reported by the <a href="https://www.theguardian.com/world/2025/feb/11/zelenskyy-europe-cannot-guarantee-ukraines-security-without-america">Guardian</a> on Tuesday could shift the geopolitical landscape, but critical details remain unclear, including what Russian-occupied regions Ukraine would demand in return.</p>
<p>In an interview with the British newspaper, Zelenskyy floated the idea of exchanging &#8220;one territory for another" with Russia, hinting at a potential swap for the Kursk region, where Ukrainian forces have held ground since a surprise incursion last August. </p>
<p>Yet, he declined to specify what occupied Ukrainian land he would seek in exchange.</p>
<h3 class="wp-block-heading">Could Trump Broker A Peace Deal? </h3>
<p>On Tuesday, the president wrote on Truth Social that he was sending Treasury Secretary <strong>Scott Bessent</strong> to Kyiv, adding, "This War MUST and WILL END SOON — Too much Death and Destruction."</p>
<p>Trump has repeatedly stated that he has already made progress with Russian President <strong>Vladimir Putin</strong>, saying the Kremlin leader also wants to end the war, the Guardian reports.</p>
<p>Zelenskyy is preparing to meet U.S. Vice President<strong> JD Vance</strong> at the Munich Security Conference later this week. </p>
<p>Vance, known for his skepticism of U.S. aid to Ukraine, has previously dismissed the conflict as a low priority. The Ukrainian leader also said he is willing to travel to Washington if a meeting with Trump is confirmed.</p>
<p>On the same day, the Trump administration secured the release of detained American teacher<strong> Marc Fogel</strong> from Russia in what National Security Advisor <strong>Mike Waltz</strong> called "a show of good faith from the Russians.&#8221;</p>
<h3 class="wp-block-heading">US Businesses In Ukraine's Reconstruction Plan</h3>
<p>Beyond a potential land swap, Zelenskyy is seeking to secure U.S. investment in Ukraine's post-war recovery. </p>
<p>He told The Guardian that American firms would receive lucrative contracts as part of the country's rebuilding efforts.</p>
<p>"Those who are helping us to save Ukraine will [have the chance to] renovate it, with their businesses together with Ukrainian businesses," Zelenskyy said, positioning the economic incentives as a way to align Trump's interests with Kyiv's.</p>
<p>Zelenskyy also dismissed suggestions that European countries could provide Ukraine with security guarantees without U.S. involvement. "Security guarantees without America are not real security guarantees," he said.</p>
<h3 class="wp-block-heading">Ceasefire Odds Rise, Markets React</h3>
<p>The latest developments have fueled speculation that a ceasefire could be in sight. Offshore betting platform Polymarket saw the odds of a ceasefire jump to 66%, while CFTC-regulated Kalshi priced the likelihood of a Trump-Putin meeting this year at 81%.</p>
<p>Markets responded cautiously. Oil prices – as tracked by the <strong>United States Oil Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) – rose 1.3% on Tuesday, yet remained relatively steady following the news. U.S. natural gas prices – as tracked by the <strong>United States Gas Fund LP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – were up 2.4%. </p>
<p><strong>Read now: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43628752/feds-powell-reiterates-no-hurry-to-cut-interest-rates-as-inflation-remains-somewhat-elevated">Fed&#8217;s Powell Reiterates No &#8216;Hurry&#8217; To Cut Interest Rates As Inflation Remains &#8216;Somewhat Elevated&#8217; (UPDATED)</a></strong></li>
</ul>
<p><em>Photo by LeStudio on Shutterstock</em></p>


Government

Regulations

Eurozone

Commodities

Global

ETFs

Ukraine Floats Land Swap With Russia As Trump Signals Peace Push

<p>In the last three months, 18 analysts have published ratings on Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $52.0, along with a high estimate of $57.00 and a low estimate of $48.00. This current average has increased by 7.84% from the previous average price target of $48.22. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739307626_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Baker Hughes among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Saurabh Pant</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Baker Hughes. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Baker Hughes compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Baker Hughes's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Baker Hughes's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BKR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Baker Hughes analyst ratings.</strong></a></p>
<h2>About Baker Hughes</h2>
<p>Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. It maintains modest exposure to offshore oil and gas production. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with a high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.</p>
<h3>Unraveling the Financial Story of Baker Hughes</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Baker Hughes displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>6.6%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Baker Hughes's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>16.01%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Baker Hughes's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.09%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Baker Hughes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.11%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.35</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Baker Hughes Stock: A Deep Dive Into Analyst Perspectives (18 Ratings)

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Delta Air Lines</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DAL, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 18 uncommon options trades for Delta Air Lines.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 61% bullish and 27%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $878,930, and 11 are calls, for a total amount of $691,867.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $72.5 for Delta Air Lines, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Delta Air Lines's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Delta Air Lines's significant trades, within a strike price range of $45.0 to $72.5, over the past month.</p>
<h3>Delta Air Lines Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306746_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$65.00</td>
<td>$320.0K</td>
<td>9.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$6.5</td>
<td>$6.3</td>
<td>$6.4</td>
<td>$55.00</td>
<td>$192.0K</td>
<td>39</td>
<td>300</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.77</td>
<td>$1.74</td>
<td>$1.87</td>
<td>$67.50</td>
<td>$169.2K</td>
<td>7.3K</td>
<td>14.7K</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$5.85</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$70.00</td>
<td>$166.5K</td>
<td>334</td>
<td>318</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.9</td>
<td>$2.87</td>
<td>$2.9</td>
<td>$65.00</td>
<td>$65.9K</td>
<td>23.1K</td>
<td>376</td>
</tr>
</tbody>
</table>
</p>
<h3>About Delta Air Lines</h3>
<p>Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.</p>
<p>Following our analysis of the options activities associated with Delta Air Lines, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Delta Air Lines</h3>
<ul>
<li>With a volume of 5,601,849, the price of DAL is down -2.23% at $64.72. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Delta Air Lines, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

A Closer Look at Delta Air Lines's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bullish approach towards Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAVA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Cava Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 52% leaning bullish and 41% bearish. Among these notable options, 2 are puts, totaling $1,122,484, and 15 are calls, amounting to $906,335.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $200.0 for Cava Group, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Cava Group options trades today is 503.15 with a total volume of 3,879.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Cava Group's big money trades within a strike price range of $60.0 to $200.0 over the last 30 days.</p>
<h3>Cava Group Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306741_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$7.05</td>
<td>$6.8</td>
<td>$7.0</td>
<td>$125.00</td>
<td>$1.0M</td>
<td>269</td>
<td>2.5K</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.9</td>
<td>$10.8</td>
<td>$11.6</td>
<td>$200.00</td>
<td>$174.0K</td>
<td>1.5K</td>
<td>252</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$11.0</td>
<td>$10.55</td>
<td>$10.78</td>
<td>$200.00</td>
<td>$107.8K</td>
<td>1.5K</td>
<td>253</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$19.7</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$135.00</td>
<td>$97.5K</td>
<td>606</td>
<td>109</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$87.2</td>
<td>$85.3</td>
<td>$85.5</td>
<td>$60.00</td>
<td>$85.5K</td>
<td>49</td>
<td>12</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cava Group</h3>
<p>Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.</p>
<p>Having examined the options trading patterns of Cava Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Cava Group Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,578,028, with CAVA's price down by -5.41%, positioned at $133.01.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cava Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


CAVA

Cava Group Unusual Options Activity For February 11

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Biogen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIIB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Biogen.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 22%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $634,880, and 5 are calls, for a total amount of $219,709.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $250.0 for Biogen during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Biogen's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale activity within a strike price range from $130.0 to $250.0 in the last 30 days. </p>
<h3>Biogen Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306736_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$11.0</td>
<td>$10.8</td>
<td>$10.9</td>
<td>$140.00</td>
<td>$492.6K</td>
<td align="right">289</td>
<td align="right">458</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.4</td>
<td>$15.1</td>
<td>$15.4</td>
<td>$160.00</td>
<td>$93.9K</td>
<td align="right">85</td>
<td align="right">102</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.2</td>
<td>$10.7</td>
<td>$10.8</td>
<td>$140.00</td>
<td>$54.0K</td>
<td align="right">289</td>
<td align="right">508</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$139.00</td>
<td>$52.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$18.1</td>
<td>$17.3</td>
<td>$18.1</td>
<td>$130.00</td>
<td>$36.2K</td>
<td align="right">17</td>
<td align="right">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>In light of the recent options history for Biogen, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Biogen</h3>
<ul>
<li>Trading volume stands at 1,318,628, with BIIB's price down by -2.5%, positioned at $138.97.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Expert Opinions on Biogen</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup persists with their Neutral rating on Biogen, maintaining a target price of $160. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BIIB

Biogen's Options Frenzy: What You Need to Know

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) has outperformed the market over the past 5 years by 11.53% on an annualized basis producing an average annual return of 23.95%. Currently, Nucor has a market capitalization of $32.51 billion. </p>
<p><strong>Buying $100 In NUE:</strong> If an investor had bought $100 of NUE stock 5 years ago, it would be worth <strong>$294.08</strong> today based on a price of $138.46 for NUE at the time of writing.</p>
<h3>Nucor's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306731_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<p><a href="https://www.newyorkfed.org/newsevents/speeches/2025/wil250211" title="https://www.newyorkfed.org/newsevents/speeches/2025/wil250211">https://www.newyorkfed.org/newsevents/speeches/2025/wil250211</a></p>


Macro Economic Events

Economics

Federal Reserve

Fed's Williams Says Labor Market In Good Balance, Not An Inflation Driver; Fed Has Made Significant Progress Lowering Inflation; Inflation Expectations Are Well Anchored; US Economy Is In A Good Place

Fed's Williams Says Monetary Policy Well Positioned To Achieve Fed Goals; Modestly Restrictive Policy Should Return Inflation To 2%; Economic Outlook Is Highly Uncertain Due In Part To Government Policy; Inflation To Hang Around 2.5% This Year, 2% In Coming Years; Us To Grow By Around 2% This Year And Next; Us Unemployment Rate Should Stay Between 4% To 4.25%

<p>Financial technology powerhouse <strong>Robinhood Markets Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) easily ranks among the top innovators, providing a convenient mechanism for the democratization of investing. </p>
<p>Naturally, Robinhood stock has absorbed significant interest, gaining about 350% over the past one-year period. Still, such astounding performances raise concerns about overvaluation — concerns that the smart money appears to be digesting.</p>
<p>In terms of the headline statistic, the biggest <a href="https://www.benzinga.com/insights/options/25/02/43628104/robinhood-markets-unusual-options-activity-for-february-11">unusual options trade</a> by far earlier today in terms of dollar value went to $50 call options featuring bullish sentiment. However, the total number of trades leaned bearishly, with 50% of investors opening trades with bearish expectations while 45% opened with bullish expectations.</p>
<p>Unfortunately, it's not such a cut-and-dry case. Late last week, the sentiment fissure was much more pronounced, with big-money traders splitting their funds 55% in the bearish direction and 34% in the bullish, with the remainder directed as neutral transactions.</p>
<p>Put another way, the most prudent approach may be to consider Robinhood stock as a volatility trade. However, there could be an argument for a directionally bullish wager considering the relative uptick in bullish transactions among the big-money traders.</p>
<p>Yes, on the surface, Robinhood&#8217;s stock seems wildly overvalued. For example, the equity currently trades at <a href="https://finance.yahoo.com/quote/hood/key-statistics">20.49-times trailing-12-month sales</a>. Around this point last year, this metric sat at only 9.62 times. However, analysts overall anticipate that Robinhood will generate $3.37 billion in revenue for fiscal 2025. Based on this projection, the forward sales multiple declines to a much more reasonable 14.2 times.</p>
<p>Moreover, investors must appreciate Robinhood's <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40752830/robinhood-shifted-from-meme-stock-to-market-contender-amid-new-products-and-global-">ambitious objectives</a>. As Barclays analyst Benjamin Budish noted last year, Robinhood's potential future growth enjoys several fresh catalysts: new products (like futures and credit cards), geographic expansion (particularly in the U.K.) and new channels, particularly in the cryptocurrency realm.</p>
<h2 class="wp-block-heading">Framing HOOD Stock as a ‘FOMO' Trade</h2>
<p>Perhaps the biggest takeaway regarding Robinhood stock from a trading perspective is that it responds aggressively to FOMO or the fear of missing out. In other words, this is a security that thrives on positive energy. However, speculators should also realize the opposite is also true: the stock price tends to tank on negative energy.</p>
<p>From a purely stochastic or temporal view, a position entered at the beginning of the week has around a 52.5% chance of rising by the end of it. The long odds continue to be above a coin toss in two and three-week intervals. However, by the end of the fourth week, the long odds dip slightly to 49.17%.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-777252" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption"><em>Image by author</em></figcaption></figure></p>
<p>On a dynamic basis (accounting for certain conditions), the probabilities fluctuate noticeably. For example, last week, the stock gained 15.2%. Historically, whenever Robinhood gained between 10% and 20% during a one-week period, the long odds for the subsequent week spiked to around 73%. By the end of the fourth subsequent week following this extreme-greed event, the long odds are still favorable at 60%.</p>
<p>Interestingly, investors do not show a tendency of buying the dips in the company&#8217;s stock. Following a weekly loss between 10% and 20%, the chances that Robinhood will rise in the subsequent week lands at only 35.3%. Over the course of four weeks, long odds are even worse at 29.4%.</p>
<p>That's not to say that these statistical tendencies guarantee a move in one direction or another because they absolutely do not. However, investors should realize that strength in Robinhood stock continues to bolster more strength. At the same time, severe corrections tend to scare off traders, adding to the high-stakes atmosphere.</p>
<h2 class="wp-block-heading">Plotting an Effective Options Strategy for Robinhood</h2>
<p>Arguably, the most sensible options-based approach for the company is to treat it as a volatility trade. One week after the aforementioned extreme-greed event (which coincides with the options chain expiring Feb. 14), the median return under the positive scenario is 3.07% while the median loss under the negative scenario is 4.93%. Based on last Friday's close as the anchor, that would target a high of $57.57 and a low of $53.11.</p>
<p>Complicating matters, though, is the wildly high <a href="https://optioncharts.io/options/HOOD/volatility-skew">implied volatility</a> (IV) of approximately 168%. Essentially, IV represents the market's anticipation of mobility in the target asset. Using reverse engineering which accounts for the time decay of options, market makers are anticipating a move of $8.27 in either direction; therefore, roughly $62.48 at the high or $45.94 at the low.</p>
<p>One approach may involve splitting the difference between the two data sets, thus targeting $60 at the high and around $50 at the low. For this trade, one could consider the 50P &#x7C; 52P &#x7C;&#x7C; 58C &#x7C; 60C long iron condor for the options chain expiring this Friday.</p>
<p>The above transaction combines the 50/52 bear put spread and the 58/60 bull call spread, with the maximum payout triggered if Robinhood stock rises to $60 or falls to $50. At time of writing, a trader risks $140 for the chance to earn a maximum of $60.</p>
<p>Of course, the long iron condor features a less-attractive reward profile because the trader is essentially paying two premiums. On the other hand, for traders who believe in the bullish statistical tendency, the framework becomes quite alluring.</p>
<p>As an example, long speculators may consider the 57/60 bull call spread for the options chain expiring March 7. This transaction requires a net debit of $99 for the chance to earn a maximum reward of $201. That's a payout of 203% compared to the long iron condor's 43% payout.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">Trump Says We Will &#8216;Take&#8217; And Cherish Gaza</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Earnings

HOOD

Options Corner: Smart Money Is In Fierce Tug-Of-War Ahead Of Robinhood Earnings

<p><strong>Reddit Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) could highlight how AI data licensing deals are helping the company's improving financials and profitability when the company reports fourth-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a></p>
<p><br /><strong>Earnings Estimates</strong>: Analysts expect Reddit to report fourth-quarter revenue of $404.63 million according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a></p>
<p>The company has beaten analyst estimates for revenue in three straight quarters since going public. Here are the quarterly revenue totals for the fiscal year:</p>
<ul>
<li>First Quarter: $242.96 million</li>
<li>Second Quarter: $281.18 million</li>
<li>Third Quarter: $348.35 million</li>
</ul>
<p>Analysts expect the company to report earnings per share of 25 cents for the fourth quarter. The company has beaten analyst estimates for three straight quarters, included the third quarter which had a profit of 16 cents per share.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/general/social-media/25/01/43291797/exclusive-will-social-media-users-leave-over-politics-new-poll-shows-this-platform-hurt-most">EXCLUSIVE: Will Social Media Users Leave Over Politics? New Poll Shows This Platform Hurt Most</a></strong></p>
<p><strong>Key Items to Watch</strong>: Reddit's earnings report comes as AI continues to be a trending topic and monetization opportunity for many companies and sectors.</p>
<p>Reddit was early to the trend of media companies being <a href="https://www.benzinga.com/news/24/03/37898537/reddit-is-selling-you-to-artificial-intelligence-firms-should-you-care">paid to license out</a> their data to the likes of Google and OpenAI for AI models. These deals have helped boost the financials for Reddit and will be among the most watched items in the quarterly results.</p>
<p>Analysts and investors expect to see strong revenue growth and improving profitability in the quarter.</p>
<p>Analysts have been bullish on Reddit in recent weeks. Here are the <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">recent analyst ratings</a> and price targets on Reddit:</p>
<ul>
<li>Raymond James: Maintained Strong Buy rating, raised price target from $200 to $250</li>
<li>Seaport Global: Initiated with Neutral rating, no price target</li>
<li>JMP Securities: Reiterated market Outperform, $190 price target</li>
<li>Roth MKM: Downgraded from Buy to Neutral, raised price target from $116 to $195</li>
</ul>
<p>Since going public in March 2024, Reddit has been one of the top-performing IPOs in recent history. Shares priced at $34 and the stock closed at $50.44 in its market debut. Shares are up significantly since that time.</p>
<p>Expectations are likely high for Reddit, which could mean a strong quarter and strong guidance is needed to send shares higher.</p>
<p><br /><strong>RDDT Price Action</strong>: Reddit stock is down 4.6% to $214.80 on Tuesday versus a 52-week trading range of $37.35 to $230.41. Reddit stock is up 29.5% year-to-date in 2024 and up over 325% in the last year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/03/37995982/3-reddit-executives-sold-too-early-and-missed-out-on-19m-in-additional-gains-from-ipo"><strong>3 Reddit Executives Sold Too Early And Missed Out On $19M In Additional Gains From IPO</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Sports Betting

RDDT

Reddit Q4 Earnings Preview: Can Recently Public Company Beat Estimates Four Straight Quarters?

<p><strong>Intel Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading higher on Tuesday, driven by comments from U.S. <strong>Vice President JD Vance </strong>about protecting American artificial intelligence and <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43635364/us-stocks-dip-as-powell-stays-cautious-intel-climbs-tesla-sinks-to-11-week-low">semiconductor technologies</a>.</p>
<p><strong>What To Know:</strong> <a href="https://www.cnbc.com/2025/02/11/intel-rises-after-vp-vance-promises-to-safeguard-american-ai-and-chips.html">According to CNBC</a>, the stock reacted to Vance's remarks at the Paris AI summit, where he pledged to block foreign adversaries from stealing and misusing AI for military and intelligence purposes.</p>
<p>Vance stated that authoritarian regimes have exploited AI for surveillance, propaganda, and military advancements and that the U.S. would take aggressive action to prevent such activities. While he did not directly mention China's DeepSeek AI, he emphasized the need for international cooperation to limit adversarial access to AI technology.</p>
<p>Intel has struggled to regain its position in the semiconductor industry after losing significant market share to competitors like Nvidia and Broadcom. The stock fell 60% last year as the company lagged in AI chip development. In its most recent earnings report, Intel posted a third consecutive quarter of declining revenue and issued a weak forecast. The company is also undergoing leadership changes following the departure of CEO <strong>Pat Gelsinger.</strong></p>
<p>Despite its challenges, Intel has secured billions in government subsidies to build semiconductor manufacturing facilities in the U.S. as part of an effort to strengthen domestic production. The company is currently led by interim co-CEOs <strong>David Zinsner and Michelle Johnston Holthaus.</strong></p>
<p><strong>INTC Price Action: </strong>Intel corporation shares were up 6.42% at $21.04 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">Benzinga pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-1024x530.png" alt="" class="wp-image-777290" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44.png 1532w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">Trump Says We Will &#8216;Take Gaza&#8217; And &#8216;Cherish It&#8217; In White House Meeting With Jordan&#8217;s King Abdullah</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


INTC

Intel Shares Are Up Today: What's Going On?

<p>Boeing&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Starliner program has turned into a costly and embarrassing failure. The aerospace giant has spent more than $2 billion on the troubled spacecraft, including $523 million in charges just in 2024, according to a filing with the U.S. Securities and Exchange Commission.&nbsp;</p>
<p>This financial catastrophe is the result of numerous delays, technical malfunctions, and growing testing and certification expenses. NASA and Boeing originally agreed to a <a href="https://www.benzinga.com/startups/24/07/40026075/boeing-wins-space-mission-contracts-owing-to-its-armies-of-lobbyists-says-spacex-ceo-elon-musk-amid">$4.2 billion contract</a> for the development of Starliner, but due to ongoing failures and significant overruns, the program is now among the most costly commercial space missions in history.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks"><strong>See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Boeing's $2 Billion Problem</h2>
<p>The Starliner program has been plagued with delays, technical failures, and massive cost overruns. The spacecraft was supposed to be NASA's second option for sending astronauts to and from the International Space Station, alongside <strong>SpaceX</strong>'s Crew Dragon. But since its first crewed test flight in June, the Starliner has faced thruster malfunctions, helium leaks, and other serious issues.</p>
<p>These problems meant <strong>Butch Wilmore</strong> and <strong>Suni Williams</strong> couldn't return home on Starliner as planned. NASA had to send the spacecraft back to Earth uncrewed and later announced that the astronauts would return on a SpaceX Crew Dragon instead. Boeing had already taken multiple financial hits on the project, including a $489 million charge in 2019 and now another $523 million in 2024, further driving up the total losses.</p>
<p><strong>Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi"><strong>Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</strong></a></strong></p>
<h2 class="wp-block-heading">Musk and Trump Stir Up Controversy</h2>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">The <a href="https://twitter.com/POTUS?ref_src=twsrc%5Etfw">@POTUS</a> has asked <a href="https://twitter.com/SpaceX?ref_src=twsrc%5Etfw">@SpaceX</a> to bring home the 2 astronauts stranded on the <a href="https://twitter.com/Space_Station?ref_src=twsrc%5Etfw">@Space_Station</a> as soon as possible. We will do so.<br /><br />Terrible that the Biden administration left them there so long.</p>
<p>&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1884365928038563880?ref_src=twsrc%5Etfw">January 28, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Despite NASA making this decision months ago, <strong>Elon Musk</strong> and <strong>Donald Trump</strong> made headlines by claiming that the astronauts were &#8220;stranded.&#8221; Musk posted on X that SpaceX would rescue the astronauts after <a href="https://www.benzinga.com/general/space/25/01/43310082/trump-calls-on-musk-to-rescue-stranded-astronauts-but-nasa-picked-spacex-last-year">Trump asked him to step in</a>. Trump went even further on his social media, saying the Biden administration had &#8220;abandoned&#8221; Wilmore and Williams in space.</p>
<p>This claim caught many by surprise because NASA had already arranged for SpaceX to bring them back as part of its Crew-9 mission, which launched in September with two empty seats specifically for their return. Despite NASA&#8217;s repeated assurances that the astronauts were never stranded and always had a way home, Musk&#8217;s remarks caused confusion.</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it"><strong><em>Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">Politics and Space Contracts</h2>
<p>Trump&#8217;s remarks and Musk&#8217;s involvement may have detrimental effects on Boeing. Trump's administration seems keen on shifting more <a href="https://www.benzinga.com/news/24/10/41414968/spacex-wins-major-us-space-force-contract-worth-734m-for-national-security-missions">NASA contracts</a> toward SpaceX. He has even <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42323934/shift4-payments-stock-drops-after-ceo-jared-isaacmans-nasa-nomination-whats-going-on">nominated <strong>Jared Isaacman</strong></a>, a SpaceX ally and <a href="https://www.benzinga.com/general/space/24/09/40842633/public-company-ceo-goes-to-space-is-there-risk-for-shareholders-when-billionaires-pursue-space-drea">private astronaut</a>, to lead NASA. This move could signal a big shift away from Boeing and toward Musk's company for future space missions.</p>
<p>Boeing, already struggling with commercial jet issues and financial losses, now faces an uncertain future in the space sector. Some analysts speculate that Boeing may exit the Starliner program altogether, especially as the ISS is set to be retired within the next five years. There were even reports that Boeing was considering selling its entire space division last year.&nbsp;</p>
<p>For now, Wilmore and Williams remain on the ISS, where they've been for over seven months—far longer than their planned one-week mission. They have continued working on ISS maintenance and spacewalks while awaiting their return.</p>
<p>NASA has confirmed that <a href="https://www.benzinga.com/24/12/42571318/return-of-astronauts-sunita-williams-and-butch-wilmore-from-iss-further-delayed-now-expected-no-earlier-than-late-march">Crew-9 will bring them home</a> in March or April, once Crew-10 arrives to replace them.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>If there was a new fund backed by Jeff Bezos offering a</strong><strong> <a href="https://www.benzinga.com/money/arrived-private-credit-fund"><strong>7-9% target yield with monthly dividends would you invest in it</strong></a>?</strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>


Boeing Has Spent $2 Billion On The Starliner Debacle As Musk's SpaceX Set To Rescue The Stranded Astronauts

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Praxis Precision Medicine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PRAX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Praxis Precision Medicine.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $160,892, and 6 are calls, for a total amount of $345,368.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $100.0 for Praxis Precision Medicine over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Praxis Precision Medicine's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Praxis Precision Medicine's significant trades, within a strike price range of $75.0 to $100.0, over the past month.</p>
<h3>Praxis Precision Medicine Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305828_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.6</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$90.00</td>
<td>$132.7K</td>
<td>72</td>
<td align="right">761</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$20.7</td>
<td>$19.9</td>
<td>$19.9</td>
<td>$75.00</td>
<td>$71.7K</td>
<td>1.6K</td>
<td align="right">37</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$90.00</td>
<td>$65.4K</td>
<td>72</td>
<td align="right">248</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.6</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$90.00</td>
<td>$64.6K</td>
<td>72</td>
<td align="right">767</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$51.1K</td>
<td>32</td>
<td align="right">250</td>
</tr>
</tbody>
</table>
</p>
<h3>About Praxis Precision Medicine</h3>
<p>Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.</p>
<h3>Praxis Precision Medicine's Current Market Status</h3>
<ul>
<li>With a volume of 291,328, the price of PRAX is down -0.09% at $84.77. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What The Experts Say On Praxis Precision Medicine</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $145.33333333333334.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Praxis Precision Medicine with a target price of $175.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $150.<br />
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Buy, setting a price target of $111. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Praxis Precision Medicine options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


What the Options Market Tells Us About Praxis Precision Medicine

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Take-Two Interactive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TTWO, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for <strong>Take-Two Interactive</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 22% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $28,520, and 8, calls, for a total amount of $389,093.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $250.0 for Take-Two Interactive over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Take-Two Interactive's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Take-Two Interactive's significant trades, within a strike price range of $150.0 to $250.0, over the past month.</p>
<h3>Take-Two Interactive Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305823_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.4</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$250.00</td>
<td>$88.2K</td>
<td>1.1K</td>
<td align="right">99</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.85</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$250.00</td>
<td>$80.0K</td>
<td>1.1K</td>
<td align="right">265</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$9.1</td>
<td>$8.6</td>
<td>$8.85</td>
<td>$250.00</td>
<td>$63.7K</td>
<td>1.1K</td>
<td align="right">173</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$70.5</td>
<td>$69.7</td>
<td>$70.5</td>
<td>$150.00</td>
<td>$35.2K</td>
<td>321</td>
<td align="right">5</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$33.9</td>
<td>$33.5</td>
<td>$33.5</td>
<td>$240.00</td>
<td>$33.5K</td>
<td>24</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Take-Two Interactive</h3>
<p>Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.</p>
<p>Following our analysis of the options activities associated with Take-Two Interactive, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Take-Two Interactive</h3>
<ul>
<li>Trading volume stands at 924,561, with TTWO's price down by -1.54%, positioned at $209.23.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 93 days.</li>
</ul>
<h3>Expert Opinions on Take-Two Interactive</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $213.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel persists with their Buy rating on Take-Two Interactive, maintaining a target price of $223.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Take-Two Interactive, targeting a price of $230.<br />
&#x2A; An analyst from MoffettNathanson has decided to maintain their Neutral rating on Take-Two Interactive, which currently sits at a price target of $170.<br />
&#x2A; An analyst from Raymond James downgraded its action to Outperform with a price target of $220.<br />
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $225.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Take-Two Interactive, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


TTWO

Take-Two Interactive's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bearish approach towards IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in IREN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 47 extraordinary options activities for IREN. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 53% bearish. Among these notable options, 20 are puts, totaling $6,390,984, and 27 are calls, amounting to $1,378,685.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $6.0 to $25.0 for IREN over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in IREN's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to IREN's substantial trades, within a strike price spectrum from $6.0 to $25.0 over the preceding 30 days.</p>
<h3>IREN 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305818_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$20.00</td>
<td>$1.2M</td>
<td>11.3K</td>
<td>3.2K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$20.00</td>
<td>$825.2K</td>
<td>11.3K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.5</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$15.00</td>
<td>$594.4K</td>
<td>50</td>
<td>1.3K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$15.00</td>
<td>$578.2K</td>
<td>50</td>
<td>5.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$20.00</td>
<td>$501.2K</td>
<td>11.3K</td>
<td>560</td>
</tr>
</tbody>
</table>
</p>
<h3>About IREN</h3>
<p>IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.</p>
<p>In light of the recent options history for IREN, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of IREN</h3>
<ul>
<li>With a volume of 6,738,850, the price of IREN is down -3.73% at $12.38. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 1 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IREN options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


IREN

Decoding IREN's Options Activity: What's the Big Picture?

<p>Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has outperformed the market over the past 10 years by 14.01% on an annualized basis producing an average annual return of 25.16%. Currently, Microsoft has a market capitalization of $3.06 trillion. </p>
<p><strong>Buying $1000 In MSFT:</strong> If an investor had bought $1000 of MSFT stock 10 years ago, it would be worth <strong>$9,432.08</strong> today based on a price of $411.62 for MSFT at the time of writing.</p>
<h3>Microsoft's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305817_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MSFT

Here's How Much You Would Have Made Owning Microsoft Stock In The Last 10 Years

Mizuho Securities analyst Nitin Kumar CFA has maintained their bullish stance on TALO stock, giving a Buy rating yesterday. Nitin Kumar CFA has giv...

Talos Energy: Strategic Developments and Attractive Valuation Justify Buy Rating

Unusual total active option classes on open include: Talos Energy (TALO), Nasdaq 100 Micro Index (.XND), Lithium Americas (LAC), The Metals Company...

Unusually active option classes on open January 17th

Talos Energy ($TALO), a pioneer in the exploration and production of oil, natural gas, and natural gas liquids, has successfully discovered commerc...

Talos Energy (TALO) Discovers Commercial Gas and the Future Looks Bright

There's a lot to be optimistic about in the Energy sector as 3 analysts just weighed in on Talos Energy (TALO – Research Report), Amplify Energy (A...

Analysts' Top Energy Picks: Talos Energy (TALO), Amplify Energy (AMPY)

Talos Energy (TALO) announced that it has appointed Paul Goodfellow as president, CEO and a member of the Talos board of directors, effective March...

Talos Energy appoints Paul Goodfellow as CEO

Talos Energy taps Shell executive Goodfellow as new CEO

In a report released today, Leo Mariani from Roth MKM maintained a Buy rating on Talos Energy (TALO – Research Report), with a price target of $13....

Talos Energy (TALO) Receives a Buy from Roth MKM

Talos Energy ( ($TALO) ) has shared an update. On February 3, 2025, Talos Energy announced the appointment of Paul Goodfellow as President, Chief E...

Talos Energy Appoints Paul Goodfellow as CEO

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 2/5/2025, According to Top Analysts

Stephens analyst Mike Scialla lowered the firm's price target on Talos Energy (TALO) to $20 from $21 and keeps an Overweight rating on the shares. ...

Talos Energy price target lowered to $20 from $21 at Stephens

AGNC

AMPY

CIFR

PENN

PYPL

SHEL

Press Releases

Talos Energy Publishes Annual Sustainability Report

Talos Energy Adopts Limited Duration Stockholder Rights Plan

Glancy Prongay & Murray LLP Announces Investigation of Talos Energy Inc. (TALO)

Talos Energy to Announce Third Quarter 2024 Results on November 11, 2024 and Host Earnings Conference Call on November 12, 2024

Talos Energy Announces Third Quarter 2024 Operational and Financial Results

Talos Energy Sells Additional Stake in Zama to Grupo Carso; Enters into a Cooperation Agreement with Control Empresarial and Terminates Stockholders Rights Plan

Talos Energy Announces Management Changes

Talos Energy Announces Successful Drilling Results at the Katmai West #2 Well in the U.S. Gulf of Mexico

Talos Energy Appoints Paul Goodfellow as President, Chief Executive Officer and Board Member

Talos Energy to Announce Fourth Quarter 2024 Results on February 26, 2025 and Host Earnings Conference Call on February 27, 2025

SHLX

Black Stone Minerals, L.P. Common units representing limited partner interests

Black Stone Minerals

CNX Resources

California Resources Corporation Common Stock

California Resources

Crescent Energy Company Class A Common Stock

Crescent Energy

Dorchester Minerals, L.P. - Common Units Representing Limited Partnership Interests

Dorchester Minerals

Greenfire Resources

Gulfport Energy Corporation Common Shares

Gulfport Energy

Granite Ridge Resources, Inc. Common Stock

Granite Ridge Resources

HighPeak Energy

Kosmos Energy

Kimbell Royalty Partners Common Units Representing Limited Partner Interests

Kimbell Royalty Partners

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Mach Natural Resources LP Common Units representing Limited Partner Interests

Mach Natural Resources

Murphy Oil

Northern Oil & Gas

Permian Basin Royalty

Riley Exploration Permian, Inc. Common Stock

Riley Exploration Permian

Sabine Royalty

SM Energy

Sable Offshore

Sitio Royalties Corp. Class A Common Stock

Sitio Royalties

TXO Partners, L.P. Common Units Representing Limited Partner Interests

TXO Partners

Vital Energy, Inc. Common Stock, par value $0.01 per share

Comments

Talos Energy

空売り

Talos Energy (NYSE:TALO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル